Heart valve study seeks best blood thinner to prevent clots and bleeding
NCT ID NCT07677410
First seen Jun 30, 2026 · Last updated Aug 11, 2026 · Updated 4 times
Summary
This study tests two blood-thinning strategies in people with severe aortic regurgitation who have had a new heart valve placed without open surgery. Participants receive either daily aspirin for a year or warfarin for six months followed by aspirin. The goal is to see which approach better prevents serious events like stroke, blood clots, and major bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aspirin and Warfarin
- What this could lead to
- If aspirin proves superior, it could simplify post-procedure care and reduce bleeding risks for patients with severe aortic regurgitation after valve replacement.
- What could go wrong
- This is a mid-stage trial; results may not apply to all patients, and warfarin carries bleeding risks while aspirin may not prevent clots as effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC REGURGITATION DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.